Naegis Pharmaceuticals is focused on developing innovative therapies for inflammatory eye diseases by targeting the leukotriene pathway, which plays a significant role in the inflammatory processes affecting the eye. The company has identified two key branches of leukotriene production: the LTB4 branch, which is a potent chemokine that attracts inflammatory cells, and the cysteinyl (cys) branch, known for inducing vascular permeability that leads to tissue damage. By blocking the production of both LTB4 and cysLTs, Naegis aims to prevent the recruitment of inflammatory cells and the associated leakage of fluid into eye tissues, thereby addressing the underlying causes of inflammation in various eye diseases.

To advance its therapeutic goals, Naegis has developed a novel class of small molecules, with N0651 being the lead candidate. This compound has shown promise as a potent inhibitor of leukotriene production and is designed to protect both the cornea and retina from damage caused by inflammation. The company’s pipeline focuses on leveraging N0651 for treating a range of eye diseases where leukotrienes are implicated, while also exploring potential applications in other inflammatory conditions beyond ophthalmology. Naegis is committed to improving patient outcomes by providing effective, non-invasive treatment options that enhance compliance and quality of life.

Canada

Naegis Pharmaceuticals is an ophthalmology-focused biopharmaceutical company developing new oral and topical therapies, active in the discovery and development of novel small molecules that target underlying chronic inflammatory processes in eye diseases.

Naegis Pharmaceuticals

Company Details